Gilead Sciences Inc. (GILD)

$75.01

-0.26

(-0.35%)▲

Market is closed - opens 7 PM, 25 Sep 2023
star icon

Gilead Sciences, Inc. is a biopharmaceutical company that develops innovative treatments for life-threatening diseases.

Insights on Gilead Sciences Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 13.6M → 6.59B (in $), with an average increase of 99.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -7.4M → 2.13B (in $), with an average increase of 100.4% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 76.8% return, outperforming this stock by 57.5%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 266.4% return, outperforming this stock by 245.9%

Performance

  • $74.36
    $75.60
    $75.01
    downward going graph

    0.87%

    Downside

    Day's Volatility :1.63%

    Upside

    0.77%

    downward going graph
  • $58.07
    $85.09
    $75.01
    downward going graph

    22.58%

    Downside

    52 Weeks Volatility :31.75%

    Upside

    11.85%

    downward going graph

Returns

PeriodGilead Sciences Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-2.02%
-1.4%
-2.1%
6 Months
-5.74%
2.2%
11.7%
1 Year
20.32%
6.0%
21.6%
3 Years
20.5%
26.3%
21.1%

Highlights

Market Capitalization
93.5B
Book Value
$16.97
Dividend Share
2.96
Dividend Yield
3.99%
Earnings Per Share (EPS)
4.35
PE Ratio
17.24
PEG Ratio
0.72
Wall Street Target Price
91.04
Profit Margin
20.03%
Operating Margin TTM
35.75%
Return On Assets TTM
9.77%
Return On Equity TTM
26.35%
Revenue TTM
27.4B
Revenue Per Share TTM
21.87
Quarterly Revenue Growth YOY
5.4%
Gross Profit TTM
21.6B
EBITDA
12.2B
Diluted Eps TTM
4.35
Quarterly Earnings Growth YOY
-0.09
EPS Estimate Current Year
6.61
EPS Estimate Next Year
7.25
EPS Estimate Current Quarter
1.64
EPS Estimate Next Quarter
1.88

Analyst Recommendation

Hold
    48%Buy
    51%Hold
    0
    0%Sell
Based on 37 Wall street analysts offering stock ratings for Gilead Sciences Inc.(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
15
Hold
19
19
20
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 21.37%

Current $75.01
Target $91.04

Company Financials

FY17Y/Y Change
Revenue
26.1B
↓ 14.09%
Net Income
4.6B
↓ 65.72%
Net Profit Margin
17.73%
↓ 26.7%
FY18Y/Y Change
Revenue
22.1B
↓ 15.24%
Net Income
5.5B
↑ 17.87%
Net Profit Margin
24.65%
↑ 6.92%
FY19Y/Y Change
Revenue
22.4B
↑ 1.46%
Net Income
5.4B
↓ 1.26%
Net Profit Margin
23.99%
↓ 0.66%
FY20Y/Y Change
Revenue
24.7B
↑ 9.98%
Net Income
123.0M
↓ 97.72%
Net Profit Margin
0.5%
↓ 23.49%
FY21Y/Y Change
Revenue
27.3B
↑ 10.6%
Net Income
6.2B
↑ 4960.98%
Net Profit Margin
22.8%
↑ 22.3%
FY22Y/Y Change
Revenue
27.3B
↓ 0.09%
Net Income
4.6B
↓ 26.23%
Net Profit Margin
16.83%
↓ 5.97%
Q1 FY22Q/Q Change
Revenue
6.6B
↓ 9.03%
Net Income
19.0M
↓ 95.03%
Net Profit Margin
0.29%
↓ 4.98%
Q2 FY22Q/Q Change
Revenue
6.3B
↓ 5.01%
Net Income
1.1B
↑ 5921.05%
Net Profit Margin
18.27%
↑ 17.98%
Q3 FY22Q/Q Change
Revenue
7.0B
↑ 12.49%
Net Income
1.8B
↑ 56.38%
Net Profit Margin
25.4%
↑ 7.13%
Q4 FY22Q/Q Change
Revenue
7.4B
↑ 4.93%
Net Income
1.6B
↓ 8.33%
Net Profit Margin
22.2%
↓ 3.2%
Q1 FY23Q/Q Change
Revenue
13.6M
↓ 99.82%
Net Income
-7.4M
↓ 100.45%
Net Profit Margin
-54.41%
↓ 76.61%
Q2 FY23Q/Q Change
Revenue
6.6B
↑ 48422.06%
Net Income
2.1B
↓ 28978.38%
Net Profit Margin
32.38%
↑ 86.79%
FY17Y/Y Change
Total Assets
70.3B
↑ 23.35%
Total Liabilities
49.8B
↑ 32.35%
FY18Y/Y Change
Total Assets
63.7B
↓ 9.4%
Total Liabilities
42.1B
↓ 15.35%
FY19Y/Y Change
Total Assets
61.6B
↓ 3.22%
Total Liabilities
39.0B
↓ 7.51%
FY20Y/Y Change
Total Assets
68.4B
↑ 11.0%
Total Liabilities
50.2B
↑ 28.76%
FY21Y/Y Change
Total Assets
68.0B
↓ 0.67%
Total Liabilities
46.9B
↓ 6.57%
Q1 FY22Q/Q Change
Total Assets
63.1B
↓ 7.17%
Total Liabilities
43.2B
↓ 7.94%
Q2 FY22Q/Q Change
Total Assets
62.9B
↓ 0.33%
Total Liabilities
42.7B
↓ 1.18%
Q3 FY22Q/Q Change
Total Assets
62.6B
↓ 0.5%
Total Liabilities
41.5B
↓ 2.71%
Q1 FY23Q/Q Change
Total Assets
349.4M
↓ 99.45%
Total Liabilities
38.0M
-
Q2 FY23Q/Q Change
Total Assets
62.3B
↑ 17741.16%
Total Liabilities
14.0B
↑ 36647.37%
FY17Y/Y Change
Operating Cash Flow
11.9B
↓ 28.62%
Investing Cash Flow
-16.1B
↑ 34.08%
Financing Cash Flow
3.4B
↓ 136.3%
FY18Y/Y Change
Operating Cash Flow
8.4B
↓ 29.4%
Investing Cash Flow
14.4B
↓ 189.33%
Financing Cash Flow
-12.3B
↓ 463.04%
FY19Y/Y Change
Operating Cash Flow
9.1B
↑ 8.86%
Investing Cash Flow
-7.8B
↓ 154.45%
Financing Cash Flow
-7.6B
↓ 38.03%
FY20Y/Y Change
Operating Cash Flow
8.2B
↓ 10.67%
Investing Cash Flow
-14.6B
↑ 86.96%
Financing Cash Flow
770.0M
↓ 110.09%
FY21Y/Y Change
Operating Cash Flow
11.4B
↑ 39.37%
Investing Cash Flow
-3.1B
↓ 78.58%
Financing Cash Flow
-8.9B
↓ 1252.86%
Q1 FY22Q/Q Change
Operating Cash Flow
1.8B
↓ 42.59%
Investing Cash Flow
-1.1B
↑ 284.89%
Financing Cash Flow
-1.8B
↓ 7.62%
Q2 FY22Q/Q Change
Operating Cash Flow
1.8B
↓ 2.07%
Investing Cash Flow
-308.0M
↓ 71.21%
Financing Cash Flow
-1.0B
↓ 44.09%
Q3 FY22Q/Q Change
Operating Cash Flow
2.9B
↑ 58.88%
Investing Cash Flow
-713.0M
↑ 131.49%
Financing Cash Flow
-2.1B
↑ 111.17%

Technicals Summary

Sell

Neutral

Buy

Gilead Sciences Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gilead Sciences Inc.
Gilead Sciences Inc.
-2.41%
-5.74%
20.32%
20.5%
0.03%
Eli Lilly And Company
Eli Lilly And Company
-0.56%
64.54%
79.04%
266.39%
420.85%
Johnson & Johnson
Johnson & Johnson
-3.46%
4.7%
-3.14%
10.19%
15.77%
Merck & Co. Inc.
Merck & Co. Inc.
-3.51%
-0.55%
23.39%
28.23%
50.52%
Abbvie Inc.
Abbvie Inc.
4.12%
-3.05%
8.17%
77.13%
62.87%
Pfizer Inc.
Pfizer Inc.
-10.14%
-18.72%
-25.42%
-9.32%
-25.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gilead Sciences Inc.
Gilead Sciences Inc.
17.24
17.24
0.72
6.61
0.26
0.1
0.04
16.97
Eli Lilly And Company
Eli Lilly And Company
76.62
76.62
2.18
9.77
0.66
0.1
0.01
12.3
Johnson & Johnson
Johnson & Johnson
32.72
32.72
3.79
9.39
0.17
0.09
0.03
28.92
Merck & Co. Inc.
Merck & Co. Inc.
87.48
87.48
1.36
3.03
0.08
0.05
0.03
15.24
Abbvie Inc.
Abbvie Inc.
31.64
31.64
1.28
11.06
0.63
0.09
0.04
7.29
Pfizer Inc.
Pfizer Inc.
8.74
8.74
1.17
3.09
0.23
0.08
0.05
17.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gilead Sciences Inc.
Gilead Sciences Inc.
Hold
$93.5B
0.03%
17.24
20.03%
Eli Lilly And Company
Eli Lilly And Company
Buy
$522.2B
420.85%
76.62
22.01%
Johnson & Johnson
Johnson & Johnson
Hold
$389.3B
15.77%
32.72
13.35%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$270.8B
50.52%
87.48
5.34%
Abbvie Inc.
Abbvie Inc.
Buy
$270.8B
62.87%
31.64
15.5%
Pfizer Inc.
Pfizer Inc.
Hold
$185.5B
-25.35%
8.74
27.55%

Institutional Holdings

  • BlackRock Inc

    10.13%

  • Vanguard Group Inc

    9.10%

  • Capital World Investors

    6.50%

  • State Street Corporation

    4.76%

  • Capital Research Global Investors

    4.65%

  • Dodge & Cox

    2.73%

Corporate Announcements

  • Gilead Sciences Inc. Dividends March,2023

    In the quarter ending March,2023. Gilead Sciences Inc. has declared dividend of $0.75

    Read More

Company Information

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Organization
Gilead Sciences Inc.
Employees
17000
CEO
Mr. Daniel P. O'Day
Industry
Health Technology

Discover More

FAQs